Selecting a PARP Inhibitor for Front Line Maintenance in Advance Ovarian Cancer

Video

Dr. Rebecca Previs discusses the role of PARP inhibitors in first line maintenance therapy in advanced ovarian cancer.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Related Content
Data from the ROSELLA trial may support relacorilant plus nab-paclitaxel as a new standard in this ovarian cancer population.

Relacorilant and Nab-Paclitaxel Significantly Extend PFS in Ovarian Cancer

Gina Mauro
June 2nd 2025
Article

Data from the ROSELLA trial may support relacorilant plus nab-paclitaxel as a new standard in this ovarian cancer population.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

The safety profile of pembrolizumab in the KEYNOTE-B96 study was comparable with prior reports of the agent, and investigators observed no new safety signals.

Pembrolizumab Combo Extends PFS in Platinum-Resistant Ovarian Cancer

Russ Conroy
May 15th 2025
Article

Data from the KEYNOTE-B96 trial also show a significant overall survival improvement with pembrolizumab-based treatment in PD-L1–positive disease.

Target Folate Receptor Alpha in Ovarian Cancer?

Target Folate Receptor Alpha in Ovarian Cancer?

Dmitriy Zamarin, MD, PhD
September 17th 2018
Podcast

Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

The FDA originally approved this thiotepa formulation as a therapy for patients with breast or ovarian cancers in June 2024.

FDA Approves Multidose Thiotepa Vial for Breast and Ovarian Cancers

Russ Conroy
April 30th 2025
Article

The regulatory decision may offer more scheduling flexibility for patients who receive thiotepa for breast or ovarian cancer.

The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

Relacorilant/Chemo Show Survival Benefit in Platinum-Resistant Ovarian Cancer

Roman Fabbricatore
April 2nd 2025
Article

The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.